NO20005005L - Nye krystallinske former av en antiviral benzimidazolforbindelse - Google Patents
Nye krystallinske former av en antiviral benzimidazolforbindelseInfo
- Publication number
- NO20005005L NO20005005L NO20005005A NO20005005A NO20005005L NO 20005005 L NO20005005 L NO 20005005L NO 20005005 A NO20005005 A NO 20005005A NO 20005005 A NO20005005 A NO 20005005A NO 20005005 L NO20005005 L NO 20005005L
- Authority
- NO
- Norway
- Prior art keywords
- crystalline forms
- new crystalline
- benzimidazole compound
- antiviral
- antiviral benzimidazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9807354.7A GB9807354D0 (en) | 1998-04-07 | 1998-04-07 | Antiviral compound |
PCT/EP1999/002214 WO1999051618A1 (en) | 1998-04-07 | 1999-04-01 | Novel crystalline forms of an antiviral benzimidazole compound |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20005005D0 NO20005005D0 (no) | 2000-10-04 |
NO20005005L true NO20005005L (no) | 2000-12-06 |
Family
ID=10829932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20005005A NO20005005L (no) | 1998-04-07 | 2000-10-04 | Nye krystallinske former av en antiviral benzimidazolforbindelse |
Country Status (28)
Country | Link |
---|---|
US (9) | US6469160B1 (is) |
EP (1) | EP1071693B1 (is) |
JP (1) | JP2002510703A (is) |
KR (1) | KR20010074472A (is) |
CN (1) | CN1303390A (is) |
AP (1) | AP2000001947A0 (is) |
AT (1) | ATE261452T1 (is) |
AU (1) | AU752877B2 (is) |
BR (1) | BR9909474A (is) |
CA (1) | CA2327494C (is) |
DE (1) | DE69915461T2 (is) |
EA (1) | EA002970B1 (is) |
EE (1) | EE04120B1 (is) |
ES (1) | ES2216503T3 (is) |
GB (1) | GB9807354D0 (is) |
HR (1) | HRP20000669A2 (is) |
HU (1) | HUP0101669A3 (is) |
ID (1) | ID27109A (is) |
IL (1) | IL138697A0 (is) |
IS (1) | IS5640A (is) |
NO (1) | NO20005005L (is) |
NZ (1) | NZ507173A (is) |
PL (1) | PL343397A1 (is) |
SK (1) | SK14832000A3 (is) |
TR (1) | TR200002860T2 (is) |
WO (1) | WO1999051618A1 (is) |
YU (1) | YU60900A (is) |
ZA (1) | ZA200005153B (is) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9807355D0 (en) | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
GB9807354D0 (en) * | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
GB0008939D0 (en) * | 2000-04-11 | 2000-05-31 | Glaxo Group Ltd | Process for preparing substituted benzimidazole compounds |
DK2767539T3 (en) | 2002-05-16 | 2017-09-11 | Janssen Sciences Ireland Uc | Pseudopolymorphic forms of an HIV protease inhibitor |
WO2005118586A1 (en) * | 2004-06-02 | 2005-12-15 | Sandoz Ag | Meropenem intermediate in crystalline form |
EP1910393A2 (en) * | 2005-07-05 | 2008-04-16 | Hetero Drugs Limited | A novel process for the preparation of didanosine using novel intermediates |
US9198862B2 (en) * | 2005-07-22 | 2015-12-01 | Rubicon Research Private Limited | Dispersible tablet composition |
US8188138B2 (en) * | 2005-09-21 | 2012-05-29 | 4Sc Ag | Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors |
BRPI0617947A2 (pt) * | 2005-10-31 | 2011-08-09 | Janssen Pharmaceutica Nv | processos para a preparação de derivados de piperazinil e diazapanil benzamida |
CA2656057C (en) * | 2006-06-16 | 2012-10-02 | H. Lundbeck A/S | Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
US7919598B2 (en) * | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
CN101568544B (zh) * | 2006-10-27 | 2016-10-26 | 西格诺药品有限公司 | 包含4‑[9‑(四氢‑呋喃‑3‑基)‑8‑(2,4,6‑三氟‑苯氨基)‑9h‑嘌呤‑2‑基氨基]‑环己烷‑1‑醇的固体形式,其组合物,及其用途 |
EP2085397A1 (en) * | 2008-01-21 | 2009-08-05 | Esteve Quimica, S.A. | Crystalline form of abacavir |
US7935817B2 (en) * | 2008-03-31 | 2011-05-03 | Apotex Pharmachem Inc. | Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof |
AR071318A1 (es) * | 2008-04-15 | 2010-06-09 | Basilea Pharmaceutica Ag | Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso |
US8097719B2 (en) * | 2008-07-15 | 2012-01-17 | Genesen Labs | Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem |
KR101043794B1 (ko) * | 2009-04-13 | 2011-06-27 | 청우산업 주식회사 | 황토판재로 제공되는 기능성 황토방 |
PT2544679T (pt) | 2010-03-12 | 2019-07-11 | Omeros Corp | Inibidores de pde-10 e composições e métodos relacionados |
CN103189360A (zh) * | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 5-ht2c激动剂的非吸湿性盐 |
US8546344B2 (en) * | 2010-10-28 | 2013-10-01 | Viropharma Incorporated | Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl)-1H-benzimidazole |
US8940707B2 (en) | 2010-10-28 | 2015-01-27 | Viropharma Incorporated | Maribavir isomers, compositions, methods of making and methods of using |
US8541391B2 (en) | 2010-10-28 | 2013-09-24 | Viropharma Incorporated | Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole |
CN103930419B (zh) * | 2011-09-30 | 2016-06-01 | 广东东阳光药业有限公司 | 阿齐沙坦的晶型及其制备方法 |
NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
NZ716462A (en) | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
US9879002B2 (en) | 2015-04-24 | 2018-01-30 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
JP2018535969A (ja) | 2015-11-04 | 2018-12-06 | オメロス コーポレーション | Pde10阻害剤の固体状態形態 |
CN111303230B (zh) * | 2020-03-09 | 2021-07-13 | 中国食品药品检定研究院 | 一种黄体酮共晶物及其制备方法和用途 |
AU2023361470A1 (en) * | 2022-10-12 | 2024-09-19 | Takeda Pharmaceutical Company Limited | Method of preparing maribavir |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3399987A (en) * | 1965-08-02 | 1968-09-03 | United States Borax Chem | 2-alkylaminobenzimidazoles as herbicides |
CH443777A (de) * | 1965-08-06 | 1968-02-15 | Agripat Sa | Verfahren zum Schützen textiler Keratinfasern vor Insektenfrass und Mittel zur Durchführung dieses Verfahrens |
US3655901A (en) * | 1970-07-30 | 1972-04-11 | Merck & Co Inc | Method of inhibiting the formation of phenylethanalamine-n-methyl transferase with 2-aminobenzimidazoles |
SE9003151D0 (sv) * | 1990-10-02 | 1990-10-02 | Medivir Ab | Nucleoside derivatives |
US5248672A (en) * | 1990-11-01 | 1993-09-28 | The Regents Of The University Of Michigan | Polysubstituted benzimidazole nucleosides as antiviral agents |
WO1994008456A1 (en) * | 1992-10-21 | 1994-04-28 | The Regents Of The University Of Michigan | Polysubstituted benzimidazoles as antiviral agents |
GB9413724D0 (en) * | 1994-07-07 | 1994-08-24 | Wellcome Found | Therapeutic nucleosides |
GB9600143D0 (en) | 1996-01-05 | 1996-03-06 | Wellcome Found | Therapeutic compounds |
GB9807355D0 (en) | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
GB9807354D0 (en) * | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
-
1998
- 1998-04-07 GB GBGB9807354.7A patent/GB9807354D0/en not_active Ceased
-
1999
- 1999-04-01 KR KR1020007011089A patent/KR20010074472A/ko not_active Application Discontinuation
- 1999-04-01 HU HU0101669A patent/HUP0101669A3/hu unknown
- 1999-04-01 DE DE69915461T patent/DE69915461T2/de not_active Expired - Lifetime
- 1999-04-01 ES ES99917935T patent/ES2216503T3/es not_active Expired - Lifetime
- 1999-04-01 ID IDW20002036A patent/ID27109A/id unknown
- 1999-04-01 IL IL13869799A patent/IL138697A0/xx unknown
- 1999-04-01 AU AU36034/99A patent/AU752877B2/en not_active Ceased
- 1999-04-01 YU YU60900A patent/YU60900A/sh unknown
- 1999-04-01 BR BR9909474-6A patent/BR9909474A/pt not_active IP Right Cessation
- 1999-04-01 TR TR2000/02860T patent/TR200002860T2/xx unknown
- 1999-04-01 CN CN99806894A patent/CN1303390A/zh active Pending
- 1999-04-01 PL PL99343397A patent/PL343397A1/xx unknown
- 1999-04-01 NZ NZ507173A patent/NZ507173A/en unknown
- 1999-04-01 US US09/647,962 patent/US6469160B1/en not_active Expired - Lifetime
- 1999-04-01 EA EA200000911A patent/EA002970B1/ru not_active IP Right Cessation
- 1999-04-01 EP EP99917935A patent/EP1071693B1/en not_active Expired - Lifetime
- 1999-04-01 WO PCT/EP1999/002214 patent/WO1999051618A1/en not_active Application Discontinuation
- 1999-04-01 SK SK1483-2000A patent/SK14832000A3/sk unknown
- 1999-04-01 JP JP2000542339A patent/JP2002510703A/ja active Pending
- 1999-04-01 AT AT99917935T patent/ATE261452T1/de not_active IP Right Cessation
- 1999-04-01 CA CA2327494A patent/CA2327494C/en not_active Expired - Lifetime
- 1999-04-01 EE EEP200000584A patent/EE04120B1/xx not_active IP Right Cessation
- 1999-04-01 AP APAP/P/2000/001947A patent/AP2000001947A0/en unknown
-
2000
- 2000-09-26 ZA ZA200005153A patent/ZA200005153B/en unknown
- 2000-09-26 IS IS5640A patent/IS5640A/is unknown
- 2000-10-04 NO NO20005005A patent/NO20005005L/no not_active Application Discontinuation
- 2000-10-09 HR HR20000669A patent/HRP20000669A2/hr not_active Application Discontinuation
-
2001
- 2001-10-29 US US10/007,272 patent/US7297683B2/en not_active Expired - Fee Related
-
2007
- 2007-10-25 US US11/924,204 patent/US7714123B2/en not_active Expired - Fee Related
-
2010
- 2010-03-26 US US12/732,302 patent/US20100179101A1/en not_active Abandoned
-
2011
- 2011-01-25 US US13/012,924 patent/US9163052B2/en not_active Expired - Fee Related
-
2013
- 2013-02-01 US US13/756,612 patent/US20130261294A1/en not_active Abandoned
-
2015
- 2015-10-12 US US14/880,600 patent/US20160030460A1/en not_active Abandoned
-
2016
- 2016-09-19 US US15/268,949 patent/US20170002035A1/en not_active Abandoned
-
2017
- 2017-10-05 US US15/725,785 patent/US20180044366A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20005005L (no) | Nye krystallinske former av en antiviral benzimidazolforbindelse | |
NO20000226L (no) | Nye spiroazabicykliske heterocykliske forbindelser | |
NO996572L (no) | Nye substituerte imidazolforbindelser | |
NO20011083L (no) | Krystallinske former av EtOC2--CH2-(R)Cgl-Aze-Pab-OH | |
PT1070058E (pt) | Hidroxiamidas de acido (4-aril-sulfonilamino)-tetra-hidropirano-4-carboxilico | |
NO983181L (no) | Nye substituerte imidazolforbindelser | |
NO20010899D0 (no) | Forbedring av ugunstige apomorfin-effekter | |
NO974605L (no) | Nye heterosykliske forbindelser | |
DK1237857T3 (da) | Nye Phenalkyloxyphenylderivater | |
NO20020030L (no) | Krystallinske 1-metylkarbapenemforbindelser | |
NO20003965D0 (no) | Nye dihydroksyheksansyre-derivater | |
FI19992855A (fi) | Valaisuolosuhteiden mittaus | |
NO20023072L (no) | Syntese av krystallinske silikoaluminofosfater | |
NO20002696D0 (no) | Nye forbindelser med cGMP-PDE-inhibitoreffekt | |
PT1246817E (pt) | Derivados de 4-fenil-1-piperazinilo, -piperidinilo e -tetra-hidropiridilo | |
NO20011790D0 (no) | Nye imidazoler med anti-inflammatorisk aktivitet | |
NO20011804D0 (no) | En forbedret fremgangsmåte for fremstilling av nye antidiabetiske midler | |
DK1196431T3 (da) | En i det væsentlige krystallinsk form af melagatran | |
NO20010553D0 (no) | Krystallinske former av osanetant | |
NO994027D0 (no) | Polymorf av zopolrestat-monohydrat | |
NO20002012L (no) | Nye polymorfe former av cipamfylline | |
EE200100017A (et) | N-tert-butüülhüdroksüülamiini uued soolad | |
PT1175417E (pt) | Compostos substituidos de benzolactamas | |
NO981216D0 (no) | Nye heterosykliske forbindelser | |
NO20004583D0 (no) | Krystallinsk form av paroxetine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |